Vaxcyte (PCVX) Valuation in Focus After VAX-31 Trial Progress and FDA Breakthrough Expansion

Vaxcyte (PCVX) just made headlines with its announcement that the VAX-31 infant Phase 2 study has advanced to the third and final stage, while also introducing strategic changes to the trial by adding an Optimized Dose arm and discontinuing the Low Dose arm. This update follows the FDA's decision to expand VAX-31’s Breakthrough Therapy designation, broadening its potential use in preventing pneumonia as well as invasive pneumococcal disease. These developments matter for investors because they not only mark clinical progress but also hint at a vaccine candidate that may challenge the current standard of care for a serious pediatric condition. Looking at Vaxcyte’s journey, the market has responded with skepticism despite the scientific momentum. Over the past year, the stock has seen a sharp decline, and this pressure continued into 2025. Even with this week’s product milestone and regulatory tailwinds, momentum in the share price remains subdued, which signals that investors are still weighing the risks of clinical development and regulatory approvals against the possibility of significant future growth. After such a challenging run, the obvious question for anyone considering Vaxcyte is whether the latest breakthrough is creating a buying window, or if the market has already priced in all the potential good news.

Price-to-Book of 1.4x: Is it justified?

Vaxcyte currently trades at a price-to-book (P/B) ratio of 1.4x, which is considered good value compared to its industry peers. This is notably below both the peer average of 7.3x and the broader US Biotech industry average of 2.2x. This suggests that the market is pricing Vaxcyte at a discount relative to other biotechnology stocks.

The price-to-book ratio is a commonly used valuation metric for companies like Vaxcyte, especially in sectors where profitability is not yet established. It compares a firm's market value to its book value and offers a snapshot of how much shareholders are paying for the net assets of the company. For early-stage biotech firms with limited revenues or ongoing losses, the P/B ratio can help investors gauge market expectations and potential undervaluation.

This lower-than-average multiple could reflect investor caution around Vaxcyte’s lack of historic profitability and ongoing clinical risks. It could also signal an opportunity if management delivers on projected revenue growth and key milestones. Investors may want to consider whether market skepticism has gone too far.

Result: Fair Value of $32.17 (UNDERVALUED)

See our latest analysis for Vaxcyte.

However, investors should be mindful of Vaxcyte’s lack of revenues and ongoing losses, as these factors could intensify volatility if clinical results disappoint.

Find out about the key risks to this Vaxcyte narrative.

Another View: What About Future Cash Flows?

Another angle to consider is the SWS DCF model, which estimates a company's value by forecasting its future cash flows. For Vaxcyte, however, there is not enough data available to run this analysis with confidence. As a result, the market remains focused on tangible metrics like book value. Could this mean the usual metrics are missing a bigger story, or is the discount really justified?

Look into how the SWS DCF model arrives at its fair value.

Stay updated when valuation signals shift by adding Vaxcyte to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own Vaxcyte Narrative

For those who interpret the figures differently or simply want to dig deeper, you can assemble your perspective using the same data in just a few minutes. Do it your way

A great starting point for your Vaxcyte research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Don't let opportunity pass you by. There are other smart ways to position your portfolio for the future. Make sure you're considering every angle before your next move.

• Capture untapped bargains by targeting stocks undervalued on future cash flow, starting with our undervalued stocks based on cash flows list.
• Supercharge your search with game-changing companies redefining healthcare, all found through our healthcare AI stocks picks.
• Access income powerhouses that generate solid returns, using our selection of dividend stocks with yields > 3% for yields over 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com